OUR VISION:

Exact Sciences is committed to helping win the war on cancer through early detection.

Learn More

Cologuard: the first and only FDA approved stool DNA noninvasive colorectal cancer screening test.*

Learn More about Cologuard
*For average risk individuals only. Click the link above and talk to your doctor to see if Cologuard is right for you.

Latest News

Exact Sciences generated $99.4 million in revenues during 2016, a 152-percent increase

  Cologuard gross margin reached 61 percent in fourth quarter MADISON, Wis., Feb. 21, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $99.4 million and completed approximately 244,000 Cologuard tests during the year ended Dec. 31, 2016. Full-year 2016 revenues and Cologuard test volume grew 152 percent and 135 percent from 2015,...Read more

CMS Proposes Inclusion of Cologuard in Medicare Advantage Star Ratings

  Cologuard offers health plans an opportunity to increase screening & improve quality ratings MADISON, Wis., Feb. 2, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is included in the Medicare Advantage Advance Notice and Draft Call letter.  Cologuard's inclusion in the final Star Ratings will allow Medicare Advantage plans to increase...Read more

FOR OUR INVESTORS

View updates on upcoming conference appearances, company news, financial reports and more.

Learn More

Exact Sciences Laboratories is dedicated to delivering the most accurate results and providing physicians and patients with world-class service.

Go To ExactLabs.com